In production
08.10.2024

a
a
a

• High frequency of inappropriate breast cancer treatments
• Difficulty in predicting individual patient response to therapies
• Current models (organoids, animals) are time-consuming, costly and not very representative of human tumours
• Delays in accessing optimal treatment, reducing the effectiveness of care
• Pioneering: ex vivo 3D model that accurately reproduces patients’ tumour characteristics
• High throughput: ability to test more than 40 drug conditions in parallel
• Accurate: comprehensive profiling using next-generation sequencing
• Fast: treatment response report in just 9 days (compared to several months with organoids or animal models)
• Support committee
• Coaching
• Health economic analysis
• Meeting with experts from the Lausanne network
• Meeting with legal experts
• In progress